Swiss drugmaker Roche will combine two production operations in Basel in a move that will cut up to 190 jobs over this year and next, it said on Thursday.
Merging the active substance and small molecule drug production lines reflects the company’s changing portfolio, focusing more on specialised drugs in smaller volumes, it said in a statement.
Small molecule substances are used in the large majority of most traditional drugs.
The company said lower overall capacity will be required as its older drugs, which require significantly higher production volumes, lose patent protection.
Roche employs about 15,000 staff in Switzerland.
By Paul Arnold
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.